Pacira biosciences u's patent litigation exparel status april 2025?

I can help, but I need one quick clarification because “Exparel status” can refer to a few different things in Pacira’s litigation landscape.

Which “Exparel” matter do you mean?

1. ANDA / generic entry litigation in the U.S. (e.g., Patents-in-suit about Exparel/bupivacaine liposome products)
2. The key appeal(s) / PTAB (IPR) decisions
3. A particular court case (case number or parties)

Also, when you say “April 2025 status,” do you want:

• the last known procedural posture (trial/appeal/settlement/mandate), or
• the current IP enforceability / “can generics launch” status, or
• Pacira’s latest PR/filings summarizing it?

If you reply with the docket/case name or parties, I’ll summarize the latest status as of April 2025 as precisely as possible (and cite where it’s coming from—court docket, USPTO/PTAB, or company filings).

If you don’t have that, tell me what you know (e.g., “it was about ANDA with a generic called ” or “it involved a patent numbered ”), and I’ll narrow it down.